MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MoonLake is viewed favorably because SLK has delivered unusually strong and durable efficacy across HS and PsA, including Week 52 pooled HiSCR75 of 67.2% and HiSCR100 of 33.1% in HS, while the Phase 3 IZAR-1 PsA readout showed 42.1% ACR50, 66.5% ACR20, and 61% PASI90 in patients with skin involvement. The company is also de-risking commercialization with on-schedule FDA BLA submission, potential Priority Review, and a recent $230M equity raise that may support self-commercialization without near-term dilution. Despite competition, SLK’s IL-17A/F Nanobody design, practical dosing advantages, and broad multi-indication potential support a compelling fundamental case for market share and longer-term profitability.

MoonLake is burdened by a large and persistent cash burn, with total operating expenses of 244,834 against no meaningful revenue shown and a net loss of 230,321, underscoring that the business remains far from self-funding. Its core spending is concentrated in research and development at 202,862, but those outlays have yet to translate into commercial sales or positive operating leverage, leaving losses per share at 3.57 on a basic and diluted basis. The weaker outlook is further supported by another projected period of elevated expenses at 231,024 and a loss before taxes of 229,788, suggesting continued dilution and financing risk as the company advances a still clinical-stage pipeline.